Article

Study to evaluate dual AMD therapy

Cleveland-The Cleveland Clinic's Cole Eye Institute will lead a large, multicenter clinical trial to explore combination therapy for wet age-related macular degeneration (AMD).

Cleveland-The Cleveland Clinic's Cole Eye Institute will lead a large, multicenter clinical trial to explore combination therapy for wet age-related macular degeneration (AMD).

The 2-year, randomized, double-masked, controlled multi-center phase IIIb study will assess the safety and efficacy of verteporfin (Visudyne, Novartis Ophthalmics) administered in conjunction with intravitreal ranibizumab (Lucentis, Genentech) in patients with subfoveal choroidal neovascularization (CNV) secondary to wet AMD. The study, which is being called DENALI, will take place at 45 centers in the United States and five in Canada.

"We are exploring the potential to improve outcomes and reduce the frequency of treatments by combining therapies that target different mechanisms responsible for the development of AMD," said Peter Kaiser, MD, the study's lead investigator and an ophthalmologist at Cole Eye Institute.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.